Busam K J, Jungbluth A A
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Adv Anat Pathol. 1999 Jan;6(1):12-8. doi: 10.1097/00125480-199901000-00002.
Melan-A/MART-1 is a recently identified new melanocytic differentiation marker, which is recognized as an antigen on melanoma cells by cytotoxic T-lymphocytes. It is of interest for clinicians as potential immunotherapeutic target and it is relevant for pathologists as a novel diagnostic marker, since two antibodies (A103 and M2-7C10) have become available to study Melan-A/MART-1 expression on archival material. Both antibodies are useful in the differential diagnosis of melanocytic tumors, especially metastatic tumors, since they are more sensitive than HMB-45. Both antibodies are also of diagnostic value in the recognition of perivascular epithelioid cell tumors (angiomyolipoma, lymphangioleiomyomatosis, and clear cell tumor). Since A103 has the unique property of staining many steroid hormone producing cells, this antibody is also of value for the recognition of tumors derived from these cells, such as adrenocortical carcinomas. Both antibodies are likely to be included in the routine diagnostic armamentarium of many immunohistochemical laboratories in the near future.
黑色素A/MART-1是一种最近鉴定出的新的黑素细胞分化标志物，被细胞毒性T淋巴细胞识别为黑色素瘤细胞上的一种抗原。它作为潜在的免疫治疗靶点引起了临床医生的兴趣，并且作为一种新型诊断标志物对病理学家也很重要，因为已有两种抗体（A103和M2-7C10）可用于研究存档材料上的黑色素A/MART-1表达。这两种抗体在黑素细胞肿瘤，尤其是转移性肿瘤的鉴别诊断中很有用，因为它们比HMB-45更敏感。这两种抗体在识别血管周围上皮样细胞瘤（血管平滑肌脂肪瘤、淋巴管平滑肌瘤病和透明细胞瘤）方面也具有诊断价值。由于A103具有染色许多产生类固醇激素细胞的独特特性，该抗体对于识别源自这些细胞的肿瘤，如肾上腺皮质癌也有价值。在不久的将来，这两种抗体可能会被纳入许多免疫组织化学实验室的常规诊断工具中。
